Literature DB >> 25567837

Low-dose quetiapine induced or worsened mania in the context of possible undertreatment.

Hun Y Millard1, Barbara A Wilson2, Douglas L Noordsy2.   

Abstract

Bipolar disorder is a mental illness with a lifetime prevalence of 2% and has a dramatic impact on quality of life. Mania is a distinct period of abnormal and sustained elevated, expansive, or irritable mood and increase in goal-directed activity or energy that lasts at least 1 week and is present for most of each day. Quetiapine is an atypical antipsychotic approved for the treatment of bipolar depression and mania. For the treatment of acute mania, a dose of 600 to 800 mg/day is recommended. There has been concern of potential induction or worsening of hypomanic or manic symptoms at low doses via the ratio of 5HT2A/D2 receptor antagonism, which at lower doses favors greater 5HT2A receptor blockade and thus increases dopamine concentrations. This article describes a case report of hypomania worsening to mania with psychotic features in a drug-naïve patient who was started on low-dose quetiapine. This case adds to the existing literature of case reports indicating that low-dose quetiapine may be associated with induction or worsening of hypomanic/manic symptoms, while acknowledging the difficulty of suggesting a causal relationship. © Copyright 2015 by the American Board of Family Medicine.

Entities:  

Keywords:  Bipolar Disorder; Mental Health; Pharmacotherapy; Psychiatry; Quetiapine

Mesh:

Substances:

Year:  2015        PMID: 25567837     DOI: 10.3122/jabfm.2015.01.140105

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  4 in total

1.  Case report of a switch to mania induced by lurasidone.

Authors:  Mark Kanzawa; Olga Hadden
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-02

2.  Electroconvulsive therapy for manic state with mixed and psychotic features in a teenager with bipolar disorder and comorbid episodic obsessive-compulsive disorder: a case report.

Authors:  Olof Rask; Klara Suneson; Eva Holmström; Beata Bäckström; Björn Axel Johansson
Journal:  J Med Case Rep       Date:  2017-12-12

3.  Dose-Dependent Biphasic Action of Quetiapine on AMPK Signalling via 5-HT7 Receptor: Exploring Pathophysiology of Clinical and Adverse Effects of Quetiapine.

Authors:  Motohiro Okada; Kouji Fukuyama; Eishi Motomura
Journal:  Int J Mol Sci       Date:  2022-08-14       Impact factor: 6.208

Review 4.  Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Cureus       Date:  2019-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.